Javascript must be enabled to continue!
Imbalanced censoring as a bias in evaluation of randomized controlled trials: A simulation-based study.
View through CrossRef
e13606 Background: Censoring imbalances between experimental and control arms in clinical trials efficacy can compromise efficacy analysis especially if surrogate endpoints are used. We conducted a simulation-based study to assess the impact of imbalanced censoring in clinical trials on the probability of false-positive outcomes. Methods: With BayesCTDesign R package we created a data set of 500,000 simulated trials. The trials had initially negative results, varying sample sizes (100-2000 patients) and median survival times (1.5-9.5 mo.) with no baseline censoring. Trials with no significant baseline differences (p > 0.2) between experimental and control arms were selected. We randomly censored samples of patients from control (0-20% of sample) and experimental (0-40%) arms for analysis. A logistic regression model was created to assess probability of positive results due to censoring (HR<1 and p value after censoring <0.05). Sample sizes and difference in % of censored subjects were predictors as well as interaction term between these variables. Results: A data set consisting of 399,946 trials was included in the analysis. After random censoring, a statistically significant positive transformation was observed in 61797 trials with corresponding HR<1 (0.59-0.91; p < 0.05) in favor of experimental arm. A logistic regression model with above mentioned variables returned a following equation (p <0.05 for all the variables): y = -6.45005797 + 0.27661437*B1 + -0.000070584*B2 + 0.000304167*B3 where B0 is the intercept, B1 – difference in percentage of censored subjects between arms (per %), B2 – sample size (per subject) and B3 – an interaction term (B1*B2). Pseudo R2 coefficient was 0.715. Based on the model we estimated a predicted probability of false-positive results for the trials. Conclusions: Clinicians and researchers should pay special attention to censoring imbalances in the clinical trials as these may have a significant impact on results consistency, validity and lead to false-positive findings. [Table: see text]
American Society of Clinical Oncology (ASCO)
Title: Imbalanced censoring as a bias in evaluation of randomized controlled trials: A simulation-based study.
Description:
e13606 Background: Censoring imbalances between experimental and control arms in clinical trials efficacy can compromise efficacy analysis especially if surrogate endpoints are used.
We conducted a simulation-based study to assess the impact of imbalanced censoring in clinical trials on the probability of false-positive outcomes.
Methods: With BayesCTDesign R package we created a data set of 500,000 simulated trials.
The trials had initially negative results, varying sample sizes (100-2000 patients) and median survival times (1.
5-9.
5 mo.
) with no baseline censoring.
Trials with no significant baseline differences (p > 0.
2) between experimental and control arms were selected.
We randomly censored samples of patients from control (0-20% of sample) and experimental (0-40%) arms for analysis.
A logistic regression model was created to assess probability of positive results due to censoring (HR<1 and p value after censoring <0.
05).
Sample sizes and difference in % of censored subjects were predictors as well as interaction term between these variables.
Results: A data set consisting of 399,946 trials was included in the analysis.
After random censoring, a statistically significant positive transformation was observed in 61797 trials with corresponding HR<1 (0.
59-0.
91; p < 0.
05) in favor of experimental arm.
A logistic regression model with above mentioned variables returned a following equation (p <0.
05 for all the variables): y = -6.
45005797 + 0.
27661437*B1 + -0.
000070584*B2 + 0.
000304167*B3 where B0 is the intercept, B1 – difference in percentage of censored subjects between arms (per %), B2 – sample size (per subject) and B3 – an interaction term (B1*B2).
Pseudo R2 coefficient was 0.
715.
Based on the model we estimated a predicted probability of false-positive results for the trials.
Conclusions: Clinicians and researchers should pay special attention to censoring imbalances in the clinical trials as these may have a significant impact on results consistency, validity and lead to false-positive findings.
[Table: see text].
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Nonignorable censoring in randomized clinical trials
Nonignorable censoring in randomized clinical trials
Background In a clinical trial, survival may be censored by the end of the study, especially for subjects who enter later in the enrollment period. If there is a trend toward bette...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
How is missing data handled in cluster randomized controlled trials? A review of trials published in the NIHR Journals Library 1997–2024
How is missing data handled in cluster randomized controlled trials? A review of trials published in the NIHR Journals Library 1997–2024
Background:
Cluster randomized controlled trials are increasingly used to evaluate the effectiveness of interventions in clinical and public health research. Ho...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Dealing with censoring in a network meta-analysis of time-to-event data
Dealing with censoring in a network meta-analysis of time-to-event data
Background
The Health Technology Assessment agencies typically require an economic evaluation considering a lifetime horizon for interventions affecting surviva...
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
ABSTRACT
Background
Research infra-structure is essential for conducting phase III cancer clinical trials as its lack precludes...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

